Stock SGHT SIGHT SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Real-time Estimate Cboe BZX
Other stock markets
 10:20:50 06/05/2024 pm IST 		5-day change 1st Jan Change
5.825 USD -2.27% Intraday chart for Sight Sciences, Inc. +0.69% +13.57%
03/05 Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed MT
02/05 Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed
MT
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M
MT
Transcript : Sight Sciences, Inc., Q1 2024 Earnings Call, May 02, 2024
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
AQ
Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024
CI
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
MT
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
AQ
Sight Sciences : SGHT Proxy - Apr'24
PU
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
AQ
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
GL
Sight Sciences, Inc. Announces the Publication of Large-Scale, Real-World Migs Study
CI
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
AQ
Sector Update: Health Care Stocks Flat Pre-Bell Wednesday
MT
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Extend Gains to Premarket
MT
Sight Sciences to Present Data From Studies of Glaucoma, Dry Eye Technologies -- Shares Jump After Hours
MT
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGHT Stock
  4. News Sight Sciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW